Dashboard
Manage Tickers

IMMPIMMUTEP Ltd

Nasdaq immutep.com


$ 2.27 $ 0.04 (1.79 %)    

Wednesday, 18-Sep-2024 09:39:15 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 473.78 $ -0.78 (-0.16 %)
DIA $ 416.40 $ -0.50 (-0.12 %)
SPY $ 562.82 $ -1.04 (-0.19 %)
TLT $ 100.18 $ -0.14 (-0.14 %)
GLD $ 237.49 $ -0.70 (-0.29 %)
$ 2.23
$ 2.29
$ 2.25 x 200
$ 2.28 x 100
$ 2.27 - $ 2.29
$ 1.58 - $ 3.34
196,907
na
264.77M
$ 0.73
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

immutep-to-present-new-data-from-eftisarc-neo-phase-ii-evaluating-novel-triple-combination-including-efti-in-soft-tissue-sarcoma
Immutep To Present New Data From EFTISARC-...
09/18/2024 12:09:02

Results from triple combination of efti, radiotherapy and KEYTRUDA® (pembrolizumab) to be presented at the Connective Tissue On...

dow-jumps-over-200-points-ny-empire-state-manufacturing-index-increases-in-september
Dow Jumps Over 200 Points; NY Empire State...
09/16/2024 13:42:08

Core News & Articles
Immutep's Efti In Combination With MSD's K...
09/16/2024 12:15:18

Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024In patients with any PD-L1 expression (...

immutep-to-present-late-breaking-abstract-in-head--neck-cancer-at-esmo-congress-2024
Immutep To Present Late-Breaking Abstract ...
08/20/2024 12:01:04

Oral presentation will detail results from the randomized TACTI-003 Phase IIb trial in first line head & neck squamous cell...

immutep-announces-first-participant-dosed-in-phase-i-study-of-imp761
Immutep Announces First Participant Dosed ...
08/14/2024 12:05:51

IMP761 is designed to enhance the "brake" function of LAG-3 on T cells to restore balance to the immune system and addr...

abbott-integra-lifesciences-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
Abbott, Integra LifeSciences And Other Big...
07/29/2024 12:24:00

immutep-announces-successful-meeting-with-fda-on-phase-iii-design-in-non-small-cell-lung-cancer-tacti-004-registrational-trial-will-enrol-750-patients-regardless-of-pd-l1-expression-in-order-to-address-the-entire-1l-nsclc-market-eligible-for-anti-pd-1-therapy
Immutep Announces Successful Meeting With ...
07/22/2024 12:03:25

Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to ...

immutep-receives-regulatory-clearance-for-phase-i-study-of-first-in-class-lag-3-agonist-antibody-designed-to-treat-autoimmune-diseases
Immutep Receives Regulatory Clearance For ...
07/17/2024 12:07:24

Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limite...

why-asp-isotopes-shares-are-trading-lower-by-9-here-are-other-stocks-moving-in-fridays-mid-day-session
Why ASP Isotopes Shares Are Trading Lower ...
07/12/2024 17:14:56

Core News & Articles
Market-Moving News for July 12th
07/12/2024 12:37:11

ZAPP: 40% | Zapp Electric Vehicles shares are trading higher after the company announced that it entered into a new standby equ...

australia-based-cancer-focused-immuteps-lead-cancer-drug-shows-meaningful-response-in-untreated-head--neck-cancer-stock-soars
Australia Based Cancer Focused Immutep's L...
07/12/2024 11:39:58

Immutep announces results from Cohort B of the TACTI-003 Phase 2b trial. The combination of eftilagimod alfa and Merck's Ke...

why-ericsson-shares-are-trading-higher-here-are-20-stocks-moving-premarket
Why Ericsson Shares Are Trading Higher; He...
07/12/2024 09:35:41

reported-earlier-immutep-announces-results-for-first-line-treatment-of-head-and-neck-squamous-cell-carcinoma-patients-with-negative-pd-l1-expression
Reported Earlier, Immutep Announces Result...
07/12/2024 07:34:02

Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to ...

levi-strauss-posts-mixed-results-joins-walgreens-aerovironment-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session
Levi Strauss Posts Mixed Results, Joins Wa...
06/27/2024 12:33:51

baird-maintains-outperform-on-immutep-lowers-price-target-to-6
Baird Maintains Outperform on Immutep, Low...
06/27/2024 11:09:35

Baird analyst Joel Beatty maintains Immutep (NASDAQ:IMMP) with a Outperform and lowers the price target from $7 to $6.

immutep-and-cardiff-university-sign-exclusive-license-for-next-generation-anti-lag-3-molecules-for-cancer
Immutep And Cardiff University Sign Exclus...
06/25/2024 12:14:11

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company d...

trading-halt-halt-status-updated-at-70000-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 7:00:...
06/05/2024 11:00:05

trading-halt-halted-at-35850-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 3:58:50 a.m. ET - ...
06/03/2024 07:58:54

reported-earlier-immutep-teams-up-with-msd-to-test-efti-and-keytruda-combination-in-phase-iii-non-small-cell-lung-cancer-trial
Reported Earlier, Immutep Teams Up With MS...
06/03/2024 05:45:56

Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD's anti-PD-1 therapy, and standard chemothera...

capital-one-initiates-coverage-on-immutep-with-overweight-rating-announces-price-target-of-10
Capital One Initiates Coverage On Immutep ...
05/17/2024 15:13:45

Capital One analyst Naureen Quibria initiates coverage on Immutep (NASDAQ:IMMP) with a Overweight rating and announces Price...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION